Drugs /

derazantinib

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Derazantinib binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells. FGFR, a receptor tyrosine kinase, is upregulated in many tumor cell types and plays a key role in tumor cellular proliferation, differentiation, angiogenesis and survival.

Clinical Trials

View Clinical Trials for derazantinib

Derazantinib has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating derazantinib, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open).

FGFR2 Fusion, FGFR2 Mutation, and FGFR1 Mutation are the most frequent biomarker inclusion criteria for derazantinib clinical trials.

Adenocarcinoma of the gastroesophageal junction, cholangiocarcinoma, and gastric adenocarcinoma are the most common diseases being investigated in derazantinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Derazantinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating derazantinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Target(s) [2]:
ARG1, FGFR1, FGFR2, FGFR3, KIT, LCK
NCIT ID [1]:
C104267

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.